‘Last year was a key year in Selvita's development’: president

One of the largest biotechnology service companies in Europe, Selvita, reported PLN 142.5 million in consolidated sales revenues, which is a 35 percent better result y/y. The Company's EBITDA was PLN 33.1 million, and the net profit was PLN 19.9 million, compared to PLN 24.8 million and PLN 14.0 million a year earlier, respectively. At the turn of the year, Selvita acquired the Croatian company Fidelta from Galapagos, strengthening its position among the leading CRO companies in Europe.